RETRACTED ARTICLE:CYP1A2 rs762551 polymorphism contributes to risk of lung cancer: A meta-analysis

Tumor Biology

Volumn 35, Issue 3, 2014, Pages 2253-2257

  Ma, Zheng ^a   Guo, Wei ^a   Gong, Taiqian ^a   Niu, Hui Jun ^a   Wang, Ru Wen ^a   Jiang, Yao Guang ^a  

^a CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

CYP1A2; Lung cancer; Meta analysis; Polymorphism

Indexed keywords

CYTOCHROME P450 1A2;

ARTICLE; CANCER RISK; CAUCASIAN; CYP1A2 GENE; EMBASE; ETHNICITY; GENETIC ASSOCIATION; GENETIC RISK; HUMAN; LUNG CANCER; MEDLINE; PRIORITY JOURNAL; PUBLISHING; QUANTITATIVE ANALYSIS; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTEMATIC REVIEW; TUMOR GENE;

CASE-CONTROL STUDIES; CYTOCHROME P-450 CYP1A2; EUROPEAN CONTINENTAL ANCESTRY GROUP; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LUNG NEOPLASMS; ODDS RATIO; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS;

EID: 84899058860     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-013-1298-6     Document Type: TB

References (23)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69-90.
2. Goldstraw P, Ball D, Jett JR, Le Chevalier T, Lim E, Nicholson AG, et al. Non-small-cell lung cancer. Lancet. 2011;378:1727-40.
3. Marshall AL, Christiani DC. Genetic susceptibility to lung cancer-light at the end of the tunnel? Carcinogenesis. 2013;34:487-502.
4. Brennan P, Hainaut P, Boffetta P. Genetics of lung-cancer susceptibility. Lancet Oncol. 2011;12:399-408.
5. Oyama T, Uramoto H, Kagawa N, Yoshimatsu T, Osaki T, Nakanishi R, et al. Cytochrome p450 in non-small cell lung cancer related to exogenous chemical metabolism. Front Biosci (Schol Ed). 2012;4:1539-46.
6. Kiyohara C, Yoshimasu K, Takayama K, Nakanishi Y. Lung cancer susceptibility: are we on our way to identifying a high-risk group? Future Oncol. 2007;3:617-27.
7. Tan XL, Spivack SD. Dietary chemoprevention strategies for induction of phase ii xenobiotic-metabolizing enzymes in lung carcinogenesis: a review. Lung Cancer. 2009;65:129-37.
8. Nebert DW, Dalton TP. The role of cytochrome p450 enzymes in endogenous signalling pathways and environmental carcinogenesis. Nat Rev Cancer. 2006;6:947-60.
9. Nishikawa A, Mori Y, Lee IS, Tanaka T, Hirose M. Cigarette smoking, metabolic activation and carcinogenesis. Curr Drug Metab. 2004;5:363-73.
10. Nebert DW, Dalton TP, Okey AB, Gonzalez FJ. Role of aryl hydrocarbon receptor-mediated induction of the cyp1 enzymes in environmental toxicity and cancer. J Biol Chem. 2004;279:23847-50.
11. Bozina N, Bradamante V, Lovric M. Genetic polymorphism of metabolic enzymes p450 (cyp) as a susceptibility factor for drug response, toxicity, and cancer risk. Arh Hig Rada Toksikol. 2009;60:217-42.
12. Gemignani F, Landi S, Szeszenia-Dabrowska N, Zaridze D, Lissowska J, Rudnai P, et al. Development of lung cancer before the age of 50: the role of xenobiotic metabolizing genes. Carcinogenesis. 2007;28:1287-93.
13. Osawa Y, Osawa KK, Miyaishi A, Higuchi M, Tsutou A, Matsumura S, et al. Nat2 and cyp1a2 polymorphisms and lung cancer risk in relation to smoking status. Asian Pac J Cancer Prev. 2007;8:103-8.
14. B'Chir F, Pavanello S, Knani J, Boughattas S, Arnaud MJ, Saguem S. Cyp1a2 genetic polymorphisms and adenocarcinoma lung cancer risk in the Tunisian population. Life Sci. 2009;84:779-84.
15. Singh AP, Pant MC, Ruwali M, Shah PP, Prasad R, Mathur N, et al. Polymorphism in cytochrome p450 1a2 and their interaction with risk factors in determining risk of squamous cell lung carcinoma in men. Cancer Biomark. 2010;8:351-9.
16. Gervasini G, Ghotbi R, Aklillu E, San Jose C, Cabanillas A, Kishikawa J, et al. Haplotypes in the 5'-untranslated region of the cyp1a2 gene are inversely associated with lung cancer risk but do not correlate with caffeine metabolism. Environ Mol Mutagen. 2013;54:124-32.
17. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557-60.
18. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177-88.
19. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719-48.
20. Aldrich MC, Selvin S, Hansen HM, Barcellos LF, Wrensch MR, Sison JD, et al. Cyp1a1/2 haplotypes and lung cancer and assessment of confounding by population stratification. Cancer Res. 2009;69:2340-8.
21. Pavanello S, Fedeli U, Mastrangelo G, Rota F, Overvad K, Raaschou-Nielsen O, et al. Role of cyp1a2 polymorphisms on lung cancer risk in a prospective study. Cancer Genet. 2012;205:278-84.
22. Zhao Y, Chen ZX, Rewuti A, Ma YS, Wang XF, Xia Q, et al. Quantitative assessment of the influence of cytochrome P450 1A2 gene polymorphism and colorectal cancer risk. PLoS One. 2013;8:e71481.
23. Tian Z, Li YL, Zhao L, Zhang CL. Role of CYP1A2 1F polymorphism in cancer risk: evidence from a meta-analysis of 46 case-control studies. Gene. 2013;524:168-74.